Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.34 +0.11 (+0.43%)
Streaming Delayed Price Updated: 1:46 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out
The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market. 
Via The Motley Fool
Dollar Dips as Government Shutdown Looms: A Volatile Start to Q4 2025
The US dollar experienced a notable weakening against major global currencies today, September 29, 2025, marking a significant shift after a period of sustained strength. This decline is largely... 
Via MarketMinute
Topics Bonds Economy Government
Global Markets Brace for Impact as US Government Shutdown Looms
Washington D.C. – Global financial markets are once again gripped by uncertainty as a potential United States government shutdown looms, threatening to disrupt critical economic data releases and send... 
Via MarketMinute
Topics Bonds Economy Workforce
These S&P500 stocks are the most active in today's session
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements. 
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
Dow Futures Defy Shutdown Fears: A Deep Dive into Market Resilience
As the U.S. government teeters on the brink of another shutdown, a seemingly counter-intuitive phenomenon is gripping financial markets: Dow futures are not only holding steady but are showing signs of... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing
Via PRLog
Topics Artificial Intelligence
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
The takeover candidate is working on a bispecific antibody, capable of simultaneously blocking two drivers of cancer. 
Via Investor's Business Daily
Topics Government
U.S. Government Teeters on Brink of Shutdown: Markets Brace for Uncertainty Amidst Data Blackout Fears
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a... 
Via MarketMinute
Topics Bonds Economy Government
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Right now, these dividend payers are top options for folks who like to set it and forget it. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers. 
Via Benzinga
Topics Government World Trade
Inside MrBeast's $5 Billion Generosity Machine — and the Hidden Costs Behind It
Internet sensation Jimmy Donaldson, better known as MrBeast, has successfully established an entertainment empire valued at over $5 billion. 
Via Benzinga
Why Pfizer's Post-COVID Future Looks Brighter Than Ever
A robust pipeline of experimental and recently launched drugs could make the next several years exciting ones to be a Pfizer shareholder. 
Via The Motley Fool
BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival
The company ran an exploratory analysis of its drug, Attruby, in patients with cardiomyopathy due to TTR amyloidosis. 
Via Investor's Business Daily
Down 55%, Should You Buy the Dip on Pfizer?
Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. 
Via The Motley Fool
Topics Intellectual Property
5 Dividend Powerhouses to Buy and Never Sell
These blue-chip giants have paid shareholders through wars, recessions, and pandemics. 
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and... 
Via MarketMinute
Topics Economy Intellectual Property
Abbott India Limited: A Deep Dive into its Robust Forecast and Valuation Outlook Amidst a Thriving Indian Pharma Market
Mumbai, India – September 27, 2025 – Abbott India Limited (NSE: ABBOTINDIA), a prominent player in the Indian pharmaceutical sector, is exhibiting a robust financial trajectory and a promising... 
Via MarketMinute
Topics Economy Intellectual Property
US Government Braces for Unprecedented Shutdown: Economic Fallout Looms as Deadline Nears
As the clock ticks towards midnight on September 30, 2025, the United States government stands on the precipice of a highly imminent and seemingly unavoidable shutdown. With just days left until the... 
Via MarketMinute
Topics Economy Government Workforce
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
The company continues to improve its pipeline. 
Via The Motley Fool
3 Magnificent Stocks Under $100 to Buy Right Now
You won't need a huge amount of cash to invest in these great pharma stocks. 
Via The Motley Fool
Pfizer is Locking in New Growth Through a New Acquisition
Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet. 
Via MarketBeat
Topics Artificial Intelligence
Pfizer Faces Court Over Depo-Provera Brain Tumor Claims
Pfizer Inc. 
Via Benzinga
Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst
President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly... 
Via Benzinga
Topics Government World Trade
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?
The pharmaceutical giant is again plunging headfirst into weight-loss drug development. 
Via The Motley Fool
Topics Intellectual Property
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
2 Top Passive Income Stocks to Buy Now
These dividend stocks offer high yields and growth catalysts that could support payouts for decades. 
Via The Motley Fool
Topics Bonds Economy Lawsuit
3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now
These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples. 
Via The Motley Fool
Topics World Trade
2 Oversold Stocks Primed to Rebound and 1 Facing Challenges
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.